Tetrabenazine is neuroprotective in Huntington's disease mice

详细信息    查看全文

• 作者：Hongyu Wang (1)
  Xi Chen (1)
  Yuemei Li (1)
  Tie-Shan Tang (2)
  Ilya Bezprozvanny (1)
  
• 刊名：Molecular Neurodegeneration
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：5
• 期：1
• 全文大小：1756KB
• 参考文献：1. MacDonald ME: Huntingtin: alive and well and working in middle management. / Sci STKE 2003, 2003:pe48. CrossRef
  2. Vonsattel JP, DiFiglia M: Huntington disease. / J Neuropathol Exp Neurol 1998, 57:369鈥?84. CrossRef
  3. The Huntington's Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. / Cell 1993, 72:971鈥?83. CrossRef
  4. Tobin AJ, Signer ER: Huntington's disease: the challenge for cell biologists. / Trends Cell Biol 2000, 10:531鈥?36. CrossRef
  5. Ross CA: Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. / Neuron 2002, 35:819鈥?22. CrossRef
  6. Harjes P, Wanker EE: The hunt for huntingtin function: interaction partners tell many different stories. / Trends Biochem Sci 2003, 28:425鈥?33. CrossRef
  7. Sugars KL, Rubinsztein DC: Transcriptional abnormalities in Huntington disease. / Trends Genet 2003, 19:233鈥?38. CrossRef
  8. Zeron MM, Fernandes HB, Krebs C, Shehadeh J, Wellington CL, Leavitt BR, Baimbridge KG, Hayden MR, Raymond LA: Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. / Mol Cell Neurosci 2004, 25:469鈥?79. CrossRef
  9. Tang T-S, Slow EJ, Lupu V, Stavrovskaya IG, Sugimori M, Llinas R, Kristal BS, Hayden MR, Bezprozvanny I: Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. / Proc Natl Acad Sci USA 2005, 102:2602鈥?607. CrossRef
  10. Shehadeh J, Fernandes HB, Zeron Mullins MM, Graham RK, Leavitt BR, Hayden MR, Raymond LA: Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. / Neurobiol Dis 2006, 21:392鈥?03. CrossRef
  11. Bezprozvanny I: Calcium signaling and neurodegenerative diseases. / Trends Mol Med 2009, 15:89鈥?00. CrossRef
  12. Gerfen CR: The neostriatal mosaic: multiple levels of compartmental organization. / Trends Neurosci 1992, 15:133鈥?39. CrossRef
  13. Sedvall G, Karlsson P, Lundin A, Anvret M, Suhara T, Halldin C, Farde L: Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease. / Eur Arch Psychiatry Clin Neurosci 1994, 243:249鈥?55. CrossRef
  14. Turjanski N, Weeks R, Dolan R, Harding AE, Brooks DJ: Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. / A PET study Brain 1995,118(Pt 3):689鈥?96.
  15. Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, Sanchez-Pernaute R, de Yebenez JG, Boesiger P, Weindl A, Maguire RP: Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. / Brain 1996,119(Pt 6):2085鈥?095. CrossRef
  16. Weeks RA, Piccini P, Harding AE, Brooks DJ: Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. / Ann Neurol 1996, 40:49鈥?4. CrossRef
  17. Ginovart N, Lundin A, Farde L, Halldin C, Backman L, Swahn CG, Pauli S, Sedvall G: PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. / Brain 1997,120(Pt 3):503鈥?14. CrossRef
  18. Backman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L: Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. / Brain 1997,120(Pt 12):2207鈥?217. CrossRef
  19. Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB, Bates GP, Young AB: Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. / Proc Natl Acad Sci USA 1998, 95:6480鈥?485. CrossRef
  20. Ariano MA, Aronin N, Difiglia M, Tagle DA, Sibley DR, Leavitt BR, Hayden MR, Levine MS: Striatal neurochemical changes in transgenic models of Huntington's disease. / J Neurosci Res 2002, 68:716鈥?29. CrossRef
  21. Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, Horiuchi A, Nairn AC, Messer A, Greengard P: Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. / Proc Natl Acad Sci USA 2000, 97:6809鈥?814. CrossRef
  22. Petersen A, Puschban Z, Lotharius J, NicNiocaill B, Wiekop P, O'Connor WT, Brundin P: Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice. / Neurobiol Dis 2002, 11:134鈥?46. CrossRef
  23. Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, Hen R: Hyperactivity and impaired response habituation in hyperdopaminergic mice. / Proc Natl Acad Sci USA 2001, 98:1982鈥?987. CrossRef
  24. Cyr M, Beaulieu JM, Laakso A, Sotnikova TD, Yao WD, Bohn LM, Gainetdinov RR, Caron MG: Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. / Proc Natl Acad Sci USA 2003, 100:11035鈥?1040. CrossRef
  25. Charvin D, Vanhoutte P, Pages C, Borrelli E, Caboche J: Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. / Proc Natl Acad Sci USA 2005, 102:12218鈥?2223. CrossRef
  26. Jakel RJ, Maragos WF: Neuronal cell death in Huntington's disease: a potential role for dopamine. / Trends Neurosci 2000, 23:239鈥?45. CrossRef
  27. Wersinger C, Chen J, Sidhu A: Bimodal induction of dopamine-mediated striatal neurotoxicity is mediated through both activation of D1 dopamine receptors and autoxidation. / Mol Cell Neurosci 2004, 25:124鈥?37. CrossRef
  28. Benchoua A, Trioulier Y, Diguet E, Malgorn C, Gaillard MC, Dufour N, Elalouf JM, Krajewski S, Hantraye P, Deglon N, Brouillet E: Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. / Hum Mol Genet 2008, 17:1446鈥?456. CrossRef
  29. Cyr M, Sotnikova TD, Gainetdinov RR, Caron MG: Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin. / Faseb J 2006, 20:2541鈥?543. CrossRef
  30. Tang TS, Chen X, Liu J, Bezprozvanny I: Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. / J Neurosci 2007, 27:7899鈥?910. CrossRef
  31. Paoletti P, Vila I, Rife M, Lizcano JM, Alberch J, Gines S: Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. / J Neurosci 2008, 28:10090鈥?0101. CrossRef
  32. Huntington Support Group: Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. / Neurology 2006, 66:366鈥?72. CrossRef
  33. Kenney C, Hunter C, Jankovic J: Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. / Mov Disord 2007, 22:193鈥?97. CrossRef
  34. Kenney C, Jankovic J: Tetrabenazine in the treatment of hyperkinetic movement disorders. / Expert Rev Neurother 2006, 6:7鈥?7. CrossRef
  35. Hayden MR, Leavitt BR, Yasothan U, Kirkpatrick P: Tetrabenazine. / Nat Rev Drug Discov 2009, 8:17鈥?8. CrossRef
  36. Tang TS, Guo C, Wang H, Chen X, Bezprozvanny I: Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model. / J Neurosci 2009, 29:1257鈥?266. CrossRef
  37. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, / et al.: Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. / Hum Mol Genet 2003, 12:1555鈥?567. CrossRef
  38. Kenney C, Hunter C, Mejia N, Jankovic J: Is history of depression a contraindication to treatment with tetrabenazine? / Clin Neuropharmacol 2006, 29:259鈥?64. CrossRef
  39. Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersen A, Hayden MR: Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. / Brain 2009, 132:919鈥?32. CrossRef
  40. Ferrante RJ, Kowall NW, Beal MF, Richardson EP Jr, Bird ED, Martin JB: Selective sparing of a class of striatal neurons in Huntington's disease. / Science 1985, 230:561鈥?63. CrossRef
  41. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr: Neuropathological classification of Huntington's disease. / J Neuropathol Exp Neurol 1985, 44:559鈥?77. CrossRef
  42. Suzuki M, Desmond TJ, Albin RL, Frey KA: Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers. / Synapse 2001, 41:329鈥?36. CrossRef
  43. Glass M, Dragunow M, Faull RL: The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. / Neuroscience 2000, 97:505鈥?19. CrossRef
  44. Richfield EK, O'Brien CF, Eskin T, Shoulson I: Heterogeneous dopamine receptor changes in early and late Huntington's disease. / Neurosci Lett 1991, 132:121鈥?26. CrossRef
  45. Filloux F, Wagster MV, Folstein S, Price DL, Hedreen JC, Dawson TM, Wamsley JK: Nigral dopamine type-1 receptors are reduced in Huntington's disease: a postmortem autoradiographic study using [3H]SCH 23390 and correlation with [3H]forskolin binding. / Exp Neurol 1990, 110:219鈥?27. CrossRef
  46. Joyce JN, Lexow N, Bird E, Winokur A: Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. / Synapse 1988, 2:546鈥?57. CrossRef
  47. Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, Hodges JR, Rosser AE, Wood NW, Brooks DJ: Huntington's disease progression. / Brain 1999, 122:2353鈥?363. CrossRef
  48. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, Frey AS, Spektor BS, Penney EB, Schilling G, / et al.: Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. / Hum Mol Genet 2000, 9:1259鈥?271. CrossRef
  49. Levine MS, Altemus KL, Cepeda C, Cromwell HC, Crawford C, Ariano MA, Drago J, Sibley DR, Westphal H: Modulatory actions of dopamine on NMDA receptor-mediated responses are reduced in D1A-deficient mutant mice. / J Neurosci 1996, 16:5870鈥?882.
  50. Flores-Hernandez J, Cepeda C, Hernandez-Echeagaray E, Calvert CR, Jokel ES, Fienberg AA, Greengard P, Levine MS: Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. / J Neurophysiol 2002, 88:3010鈥?020. CrossRef
  51. Yan Z, Hsieh-Wilson L, Feng J, Tomizawa K, Allen PB, Fienberg AA, Nairn AC, Greengard P: Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin. / Nat Neurosci 1999, 2:13鈥?7. CrossRef
  52. Tang TS, Tu H, Wang Z, Bezprozvanny I: Modulation of type 1 inositol (1,4,5)-trisphosphate receptor function by protein kinase A and protein phosphatase 1alpha. / J Neurosci 2003, 23:403鈥?15.
  53. Tang TS, Bezprozvanny I: Dopamine receptor-mediated Ca(2+) signaling in striatal medium spiny neurons. / J Biol Chem 2004, 279:42082鈥?2094. CrossRef
  54. Chen N, Luo T, Wellington C, Metzler M, McCutcheon K, Hayden MR, Raymond LA: Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. / J Neurochem 1999, 72:1890鈥?898. CrossRef
  55. Song C, Zhang Y, Parsons CG, Liu YF: Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-D-aspartate receptors. / J Biol Chem 2003, 278:33364鈥?3369. CrossRef
  56. Sun Y, Savanenin A, Reddy PH, Liu YF: Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. / J Biol Chem 2001, 276:24713鈥?4718. CrossRef
  57. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA: Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. / Neuron 2002, 33:849鈥?60. CrossRef
  58. Tang T-S, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I: Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. / Neuron 2003, 39:227鈥?39. CrossRef
  59. Bohnen NI, Koeppe RA, Meyer P, Ficaro E, Wernette K, Kilbourn MR, Kuhl DE, Frey KA, Albin RL: Decreased striatal monoaminergic terminals in Huntington disease. / Neurology 2000, 54:1753鈥?759.
  60. Bohnen NI, Frey KA: The role of positron emission tomography imaging in movement disorders. / Neuroimaging Clin N Am 2003, 13:791鈥?03. CrossRef
  61. Rung JP, Rung E, Helgeson L, Johansson AM, Svensson K, Carlsson A, Carlsson ML: Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. / J Neural Transm 2008, 115:899鈥?08. CrossRef
  62. Tadori Y, Kitagawa H, Forbes RA, McQuade RD, Stark A, Kikuchi T: Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208鈥?12. / Eur J Pharmacol 2007, 574:103鈥?11. CrossRef
  63. Cryan JF, Markou A, Lucki I: Assessing antidepressant activity in rodents: recent developments and future needs. / Trends Pharmacol Sci 2002, 23:238鈥?45. CrossRef
  64. Porsolt RD, Anton G, Blavet N, Jalfre M: Behavioural despair in rats: a new model sensitive to antidepressant treatments. / Eur J Pharmacol 1978, 47:379鈥?91. CrossRef
  65. Porsolt RD, Le Pichon M, Jalfre M: Depression: a new animal model sensitive to antidepressant treatments. / Nature 1977, 266:730鈥?32. CrossRef
  
• 作者单位：Hongyu Wang (1)
  Xi Chen (1)
  Yuemei Li (1)
  Tie-Shan Tang (2)
  Ilya Bezprozvanny (1)
  
  1. Department of Physiology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, 75390, USA
  2. State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, 1 Beichen West Road, Chaoyang District, Beijing, 100101, PR, China
  

文摘

Background Huntington's disease (HD) is a neurodegenerative disorder caused by a polyglutamine (polyQ) expansion in Huntingtin protein (Htt). PolyQ expansion in Httexp causes selective degeneration of striatal medium spiny neurons (MSN) in HD patients. A number of previous studies suggested that dopamine signaling plays an important role in HD pathogenesis. A specific inhibitor of vesicular monoamine transporter (VMAT2) tetrabenazine (TBZ) has been recently approved by Food and Drug Administration for treatment of HD patients in the USA. TBZ acts by reducing dopaminergic input to the striatum. Results In previous studies we demonstrated that long-term feeding with TBZ (combined with L-Dopa) alleviated the motor deficits and reduced the striatal neuronal loss in the yeast artificial chromosome transgenic mouse model of HD (YAC128 mice). To further investigate a potential beneficial effects of TBZ for HD treatment, we here repeated TBZ evaluation in YAC128 mice starting TBZ treatment at 2 months of age ("early" TBZ group) and at 6 months of age ("late" TBZ group). In agreement with our previous studies, we found that both "early" and "late" TBZ treatments alleviated motor deficits and reduced striatal cell loss in YAC128 mice. In addition, we have been able to recapitulate and quantify depression-like symptoms in TBZ-treated mice, reminiscent of common side effects observed in HD patients taking TBZ. Conclusions Our results further support therapeutic value of TBZ for treatment of HD but also highlight the need to develop more specific dopamine antagonists which are less prone to side-effects.